Pharming Intellectual Property B.V.
Records under this name other than the patents Pharming Intellectual Property B.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
Back to Pharming Intellectual Property B.V.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,067,713 | C1 Inhibitor Produced in the Milk of Transgenic Non--Human Mammals Term ended Term ended Oct 7, 2026 · High confidence | Term ended | Term ended Oct 7, 2026 | High confidence |
| US RE43,691 | C1 Inhibitor with Short Half-Life Transient Treatment Term ended Term ended May 14, 2024 · Low confidence | Term ended | Term ended May 14, 2024 | Low confidence |
| US 6,713,662 | Production of collagen in the milk of transgenic mammals Formerly held Term ended Term ended Jun 27, 2022 · From the USPTO record | Term ended | Term ended Jun 27, 2022 | From the USPTO record |
| US 9,962,431 | Treatment of bleeding with low half-life fibrinogen Formerly held Lapsed on the fee record Ended May 8, 2022 · From the USPTO record | Lapsed on the fee record | Ended May 8, 2022 | From the USPTO record |
| US 8,557,773 | Treatment of bleeding with low half-life fibrinogen Formerly held Lapsed on the fee record Ended Oct 15, 2021 · From the USPTO record | Lapsed on the fee record | Ended Oct 15, 2021 | From the USPTO record |
| US 7,045,677 | Fusion Proteins Incorporating Lysozyme Term ended Term ended Feb 22, 2021 · Medium confidence | Term ended | Term ended Feb 22, 2021 | Medium confidence |
| US 9,546,381 | Use of Anticoagulants in the Production of Recombinant Proteins in the Milk of Transgenic Animals Lapsed on the fee record Ended Jan 17, 2021 · High confidence | Lapsed on the fee record | Ended Jan 17, 2021 | High confidence |
| US 6,740,736 | Purification of fibrinogen from milk by use of cation exchange chromatography Formerly held Term ended Term ended Mar 12, 2020 · From the USPTO record | Term ended | Term ended Mar 12, 2020 | From the USPTO record |
| US 7,655,226 | Treatment of Pompe's Disease Formerly held Term ended Ended no later than Dec 16, 2019 · Low confidence | Term ended | Ended no later than Dec 16, 2019 | Low confidence |
| US 9,212,215 | Treatment of bleeding with low half-life fibrinogen Formerly held Lapsed on the fee record Ended Dec 15, 2019 · From the USPTO record | Lapsed on the fee record | Ended Dec 15, 2019 | From the USPTO record |